Welcome to our dedicated page for Connect Biopharma Holdings news (Ticker: CNTB), a resource for investors and traders seeking the latest updates and insights on Connect Biopharma Holdings stock.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) is a clinical-stage biopharmaceutical company focused on inflammatory diseases, particularly asthma and chronic obstructive pulmonary disease (COPD). Its news flow centers on the development of its lead antibody candidate, rademikibart, and on corporate and regulatory milestones that shape the company’s trajectory.
Readers following CNTB news can expect regular updates on clinical progress, including recruitment status and topline data timing for the Phase 2 Seabreeze STAT asthma and Seabreeze STAT COPD studies, which evaluate rademikibart as an adjunct treatment for acute exacerbations. Company announcements also highlight new mechanism of action findings, post-hoc analyses of Phase 2b asthma data, and presentations at major medical meetings such as the European Respiratory Society Congress, the American Thoracic Society International Conference, and the European Academy of Allergy and Clinical Immunology Congress.
News items frequently cover regulatory and partnership developments, including the exclusive license and collaboration agreement with Simcere Pharmaceutical Co., Ltd. in Greater China and the submission and acceptance of a New Drug Application for rademikibart for atopic dermatitis by China’s National Medical Products Administration. Investors also see coverage of capital markets actions, such as the termination of the company’s American Depositary Receipt program and the direct listing of its ordinary shares on the Nasdaq Global Market under the symbol CNTB.
Additional CNTB news includes financial results, board appointments, and community initiatives, such as the collaboration with the Jovante Woods Foundation to expand asthma education programs. For investors, analysts, and healthcare observers, this news page provides a centralized view of Connect Biopharma’s clinical, regulatory, financial, and outreach activities related to rademikibart and its broader inflammatory disease focus.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Connect Biopharma (Nasdaq: CNTB) announced that it is on track to submit a New Drug Application (NDA) for its lead drug candidate, CBP-201, for the treatment of moderate-to-severe atopic dermatitis in China by the end of Q1 2024. The submission could lead to potential approval by 2025. Encouraging results from pivotal trials in China and global data presented at the AAD Annual Meeting support the efficacy of CBP-201. Connect Biopharma has also completed enrollment for a Phase 2 global trial in asthma and reported positive topline data from the ongoing China pivotal trial for CBP-201. However, the company reported a net loss of RMB 797.1 million in 2022, a decrease from RMB 1,306.8 million in 2021, while its cash reserves declined to RMB 1,127.3 million. R&D expenses increased to RMB 652.2 million due to advancing clinical trials.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) presented data from Stage 1 of a pivotal trial for CBP-201 at the American Academy of Dermatology Annual Meeting. The trial, involving 255 adults with moderate-to-severe atopic dermatitis, met all primary and secondary endpoints, showing rapid symptom relief—some within a week—and no efficacy plateau by Week 16. Notably, 30.3% of treated patients achieved clear or almost clear skin. The drug demonstrated a favorable safety profile with mostly mild-to-moderate adverse effects. CEO Zheng Wei highlighted CBP-201's potential for flexible dosing and high unmet medical need in dermatology.
Connect Biopharma Holdings Limited (NASDAQ: CNTB) announced promising findings from a Phase 2b global trial for its drug, CBP-201, aimed at treating moderate-to-severe atopic dermatitis (AD). The results, presented at the American Academy of Dermatology Annual Meeting, demonstrated significant improvements in AD symptoms across multiple body regions as early as Week 2, with sustained results observed up to Week 16. Notably, the study showed a substantial decrease in EASI scores, with improvements in erythema and other signs of AD. The trial supports CBP-201's potential as an effective treatment option with flexible dosing regimens.
Connect Biopharma (NASDAQ: CNTB) announced that two abstracts from its CBP-201 clinical development program for atopic dermatitis (AD) have been accepted for presentation at the American Academy of Dermatology (AAD) meeting in New Orleans, March 17-21, 2023. The global Phase 2b CBP-201 trial data will be shared as an online e-poster with an oral presentation on March 17, while the China trial data will feature in a late-breaking oral presentation on March 18. CEO Zheng Wei expressed enthusiasm over the acceptance of these findings, which are expected to highlight CBP-201's differentiation in treating AD.
Connect Biopharma Holdings Limited (Nasdaq: CNTB), a clinical-stage biopharmaceutical firm focused on T cell-driven therapies, will present at several conferences in February and March 2023. Notable events include the SVB Securities Global Biopharma Conference on February 15 at 4:10 PM Eastern and the BioCom Global Partnering and Investor Conference from February 28 to March 2. The company is advancing a pipeline of therapies for chronic inflammatory diseases, targeting conditions like atopic dermatitis, asthma, and ulcerative colitis. Key product candidates include CBP-201 and CBP-307.